IDXX vs COR vs PAHC Stock Comparison

Idexx Laboratories, Cencora and Phibro Animal Health Prices as of Oct 23, 2026 Peers: Industry group
COR Cencora, Inc.
$330.91 +6.0% 1M +0.7% 1Y
Market cap
$63.77B
P/E
24.3x
Revenue (TTM)
$332.77B
Div. yield
0.01%
Drug Distribution Healthcare
3 wins

Head to Head

12 decided of 12

Idexx Laboratories leads on 5 of the 12 questions below (Idexx Laboratories 5, Phibro Animal Health 4, Cencora 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionIDXXCORPAHCLeader
Larger companyMarket capitalisation $45.01B $63.77B $1.58B COR
Cheaper on earningsLower P/E, profitable companies only 39.5x 24.3x 15.9x PAHC
Cheaper on forward earningsLower price / next fiscal year consensus EPS 35.9x 19.4x 11.3x PAHC
Faster revenue growthRevenue growth, trailing twelve months +12.8% +5.1% +17.1% PAHC
More profitableNet margin, trailing twelve months 25.0% 0.8% 6.6% IDXX
Better return on capitalReturn on invested capital 45.6% 14.4% 14.2% IDXX
Less leveragedLower net debt / EBITDA 0.5x 2.2x 2.1x IDXX
Higher dividend yieldTrailing dividend yield 0.00% 0.01% 0.01% PAHC
Better 1-year returnPrice return, last 12 months -12.2% +0.7% -5.5% COR
Better 5-year returnAnnualised price return, 5 years -3.0%/yr +21.8%/yr +11.5%/yr COR
Less volatileAnnualised volatility, 1 year 32.0% 32.8% 55.6% IDXX
Higher overall scoreMean of the five percentile scores vs peers 77/100 52/100 68/100 IDXX

Percentile Scorecard

IDXXCORPAHC

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisIDXXCORPAHC
Valuation 75 #159 of 624 63 #10 of 25 92 #51 of 624
Growth 75 #149 of 603 74 #7 of 24 85 #90 of 603
Profitability 97 #17 of 555 57 #11 of 24 85 #82 of 555
Financial Health 46 #355 of 657 24 #20 of 26 26 #486 of 657
Shareholder Returns 93 #27 of 370 44 #10 of 17 53 #173 of 370
Overall 77 52 68
  • IDXX ranked among 671 companies in Pharmaceuticals and Biotechnology
  • COR ranked among 27 companies in Healthcare Payers and Distributors
  • PAHC ranked among 671 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodIDXXCORPAHCSPY
1 month +7.3%+6.0%+13.8% -1.0%
3 months +3.0%+6.8%+14.0% +2.9%
6 months -1.0%+7.4%-29.7% +6.4%
Year to date -17.2%-2.0%+3.9% +11.4%
1 year -12.2%+0.7%-5.5% +13.1%
3 years +30.1%+75.1%+244.6% +79.4%
3 years, per year +9.2%+20.5%+51.1% +21.5%
5 years -14.0%+168.3%+72.1% +67.7%
5 years, per year -3.0%+21.8%+11.5% +10.9%
10 years +407.2%+313.5%+51.7% +255.2%
10 years, per year +17.6%+15.3%+4.3% +13.5%

Risk

MeasureIDXXCORPAHCSPY
Volatility, 1Y 32.0%32.8%55.6% 12.7%
Downside volatility, 1Y 31.3%39.8%59.8% 12.7%
Beta vs S&P 500, 1Y 0.80-0.130.75 1.00
Return / volatility, 1Y -0.380.02-0.10 1.03
Max drawdown, 5Y -51.3%-32.6%-57.9% -25.4%
From 52-week high -26.9%-11.7%-34.9% -2.5%
52-week high $766.68$374.75$59.58 $779.14
52-week low $504.70$252.74$28.52 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleIDXXCORPAHC
P/E now vs peer median 38.8xmedian 17.2x 24.4xmedian 24.5x 15.8xmedian 17.2x
P/S now vs peer median 9.7xmedian 8.8x 0.2xmedian 0.3x 1.0xmedian 8.8x
EV/EBITDA now vs peer median 27.9xmedian 16.0x 17.5xmedian 14.4x 8.3xmedian 16.0x
P/FCF now vs peer median 35.2xmedian 17.8x 15.6xmedian 15.8x 159.5xmedian 17.8x
P/B now vs peer median 27.4xmedian 2.1x 19.5xmedian 2.5x 4.1xmedian 2.1x
PEG now vs peer median 2.57median 0.32 1.36median 1.35 0.35median 0.32

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsIDXXCORPAHC
Revenue $4.55B $332.77B $1.52B
Gross profit $2.84B $13.22B $512.52M
Operating income $1.46B $3.04B $194.40M
Net income $1.14B $2.65B $99.72M
Free cash flow $1.25B $4.06B $9.87M
R&D $261.47M – –
EPS (diluted) $14.37 $13.53 $2.43
Cash & equivalents $196.93M $2.82B $61.42M
Total debt $4.03B $11.72B $2.49B
Shares (diluted) 79.31M 193.94M 40.96M
Enterprise value $44.23B $52.66B $1.26B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricIDXXCORPAHC
P/E 38.8x 24.4x 15.8x
P/FCF 35.2x 15.6x 159.5x
P/Operating cash flow 32.2x 13.1x 22.8x
P/S 9.7x 0.2x 1.0x
P/B 27.4x 19.5x 4.1x
P/Tangible book 29.2x -23.5x 4.4x
EV/EBITDA 27.9x 17.5x 8.3x
EV/EBIT 30.8x 23.7x 10.8x
EV/Revenue 9.9x 0.2x 1.4x
EV/FCF 35.9x 17.7x 213.7x
EV/Operating cash flow 32.8x 14.9x 30.6x
PEG (3Y EPS CAGR) 2.57 1.36 0.35

Growth

14 metrics
MetricIDXXCORPAHC
Revenue growth (1Y) 12.8% 5.1% 17.1%
Revenue CAGR (3Y) 9.0% 9.4% 15.8%
Gross profit growth (1Y) 14.4% 20.0% 28.1%
Gross profit CAGR (3Y) 10.5% 15.0% 19.8%
Operating income growth (1Y) 16.2% 11.1% 76.0%
Operating income CAGR (3Y) 11.7% 9.5% 39.3%
Net income growth (1Y) 15.6% 38.9% 106.6%
Net income CAGR (3Y) 12.9% 16.2% 45.2%
EPS growth (1Y) 18.1% 39.3% 105.2%
EPS CAGR (3Y) 15.1% 17.9% 44.6%
Operating cash flow growth (1Y) 51.4% 176.7% -13.9%
Operating cash flow CAGR (3Y) 22.5% 14.1% 73.0%
Free cash flow growth (1Y) 59.9% 255.7% -76.4%
Free cash flow CAGR (3Y) 28.4% 13.3% 31.2%

Profitability

14 metrics
MetricIDXXCORPAHC
Gross margin 62.4% 4.0% 33.8%
EBITDA margin 35.4% 1.2% 16.8%
Operating margin 32.0% 0.9% 12.8%
Pretax margin 31.3% 1.1% 9.0%
Net margin 25.0% 0.8% 6.6%
FCF margin 27.5% 1.2% 0.6%
Operating cash flow margin 30.1% 1.4% 4.5%
Return on equity 71.9% 77.4% 26.7%
Return on assets 33.4% 3.2% 6.8%
Return on invested capital 45.6% 14.4% 14.2%
Return on capital employed 68.6% 12.9% 16.8%
Asset turnover 1.3x 4.0x 1.0x
Cash conversion (OCF / net income) 1.2x 1.8x 0.7x
Stock comp / revenue 1.4% 0.0% 0.1%

Financial Health

11 metrics
MetricIDXXCORPAHC
Debt / assets 28.1% 14.0% 41.1%
Debt / equity 0.6x 3.6x 1.6x
Net debt / EBITDA 0.5x 2.2x 2.1x
Debt / FCF 0.8x 2.9x 62.5x
Liabilities / assets 53.2% 96.1% 74.3%
Equity / assets 46.8% 3.9% 25.7%
Interest coverage 38.6x – 4.2x
Current ratio 1.2x 0.9x 3.0x
Quick ratio 0.7x 0.5x 1.1x
Cash ratio 0.2x 0.0x 0.3x
Altman Z-score 20.14 4.66 3.11

Shareholder Returns

7 metrics
MetricIDXXCORPAHC
Dividend yield – 0.7% 1.2%
Net buyback yield 2.4% 1.6% –
Shareholder yield 2.4% 2.3% 1.2%
Payout ratio (earnings) – 17.7% 19.5%
Payout ratio (FCF) – 11.5% 197.3%
Dividend growth (1Y) – 8.7% 0.1%
Dividend CAGR (3Y) – 5.7% 0.0%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusIDXXCORPAHC
Forward P/E 35.9xFY2026 19.4xFY2026 11.3xFY2027
EPS, next fiscal year $15.62FY2026 $17.08FY2026 $3.43FY2027
EPS growth, next FY +19.4%FY2026 +6.7%FY2026 +6.5%FY2027
EPS growth, the year after +13.0% +11.8% +9.6%
Revenue, next fiscal year $5.00BFY2026 $328.67BFY2026 $1.53BFY2027
Revenue growth, next FY +16.3%FY2026 +2.3%FY2026 +0.6%FY2027
Revenue growth, the year after +0.6% -0.5% -0.2%
IDXX estimates →COR estimates →PAHC estimates →

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersIDXXCORPAHC
Held by institutions 93.6% 94.7% 99.1%
Institutions holding 1,289 1,342 208
Change in shares held, QoQ +4.1% +15.7% +3.1%
Institutions buying 587 542 117
Institutions selling 496 609 73
Buyers to sellers 1.18 0.89 1.60
IDXX holders →COR holders →PAHC holders →

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

IDXXCORPAHC
IDXX 1.00 0.12 0.31
COR 0.12 1.00 0.12
PAHC 0.31 0.12 1.00

Add a Peer

Largest companies in the same industry
IDXX · Animal Health
+MRKMerck +ZTSZoetis +ELANElanco Animal Health +CHWYChewy +NEOGNeogen +BFLYButterfly Network +ANIKAnika Therapeutics +ICCCImmucell
Plot all 33 Animal Health stocks → Plot all 37 Drug Distribution stocks →

Related Comparisons

IDXX vs MRKMerck IDXX vs ZTSZoetis IDXX vs ELANElanco Animal Health IDXX vs CHWYChewy

Frequently Asked Questions

Which is bigger, IDXX, COR and PAHC?

Cencora (COR) is the largest by market capitalisation: Idexx Laboratories (IDXX) $45.01B, Cencora (COR) $63.77B, Phibro Animal Health (PAHC) $1.58B.

Which stock is cheaper, IDXX, COR and PAHC?

Phibro Animal Health (PAHC) trades on the lowest price-to-earnings ratio (Idexx Laboratories (IDXX) 39.5x, Cencora (COR) 24.3x, Phibro Animal Health (PAHC) 15.9x). On next year's consensus earnings, Phibro Animal Health (PAHC) is cheapest (Idexx Laboratories (IDXX) 35.9x, Cencora (COR) 19.4x, Phibro Animal Health (PAHC) 11.3x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Phibro Animal Health (PAHC) grew revenue fastest over the trailing twelve months: Idexx Laboratories (IDXX) +12.8%, Cencora (COR) +5.1%, Phibro Animal Health (PAHC) +17.1%.

Which company is more profitable?

Idexx Laboratories (IDXX) has the highest net margin (Idexx Laboratories (IDXX) 25.0%, Cencora (COR) 0.8%, Phibro Animal Health (PAHC) 6.6%). On return on invested capital, Idexx Laboratories (IDXX) leads (Idexx Laboratories (IDXX) 45.6%, Cencora (COR) 14.4%, Phibro Animal Health (PAHC) 14.2%).

Which stock has performed better?

Over the past year Cencora (COR) returned the most: Idexx Laboratories (IDXX) -12.2%, Cencora (COR) +0.7%, Phibro Animal Health (PAHC) -5.5%. Over five years, Cencora (COR) compounded fastest (Idexx Laboratories (IDXX) -3.0%/yr, Cencora (COR) +21.8%/yr, Phibro Animal Health (PAHC) +11.5%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Phibro Animal Health (PAHC) has the highest dividend yield: Idexx Laboratories (IDXX) 0.00%, Cencora (COR) 0.01%, Phibro Animal Health (PAHC) 0.01%. Idexx Laboratories (IDXX) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Idexx Laboratories (IDXX) has been the steadiest (Idexx Laboratories (IDXX) 32.0%, Cencora (COR) 32.8%, Phibro Animal Health (PAHC) 55.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, IDXX, COR and PAHC?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Idexx Laboratories (IDXX) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.